The CDC27 antibody targets the CDC27 protein, a critical component of the Anaphase-Promoting Complex/Cyclosome (APC/C), a multi-subunit E3 ubiquitin ligase essential for cell cycle regulation. CDC27 (also known as APC3) functions as a scaffold protein within the APC/C, facilitating its assembly and interaction with co-activators like CDC20 and CDH1. The APC/C governs progression through mitosis and the G1 phase by targeting key cell cycle regulators, such as securin and cyclin B, for ubiquitin-mediated proteasomal degradation, ensuring timely transitions between cell cycle phases. Antibodies against CDC27 are widely used in research to study APC/C structure, function, and dynamics during cell division. They are applied in techniques like Western blotting, immunofluorescence, and immunoprecipitation to assess APC/C activity, subunit composition, or localization in various cellular contexts. Dysregulation of CDC27 or APC/C is linked to genomic instability, mitotic errors, and cancer, making these antibodies valuable tools in oncology and cell biology studies. Additionally, CDC27 antibodies help investigate checkpoint mechanisms, DNA damage responses, and potential therapeutic targets for diseases involving cell cycle aberrations. Commercial CDC27 antibodies are typically validated for specificity across human, mouse, and rat models.